U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Maturity-onset diabetes of the young type 8(MODY8)

MedGen UID:
342845
Concept ID:
C1853297
Disease or Syndrome
Synonyms: Diabetes and pancreatic exocrine dysfunction; Diabetes mellitus MODY type 8; Diabetes-pancreatic exocrine dysfunction syndrome; Maturity-Onset Diabetes of the Young Type 8, with Exocrine Dysfunction; MODY8
SNOMED CT: Diabetes-pancreatic exocrine dysfunction syndrome (609575003); Maturity-onset diabetes of the young, type 8 (609575003); MODY8 (maturity-onset diabetes of the young type 8) (609575003)
 
Gene (location): CEL (9q34.13)
 
Monarch Initiative: MONDO:0012348
OMIM®: 609812

Definition

Maturity-onset diabetes of the young type 8 (MODY8) is characterized by onset of diabetes before age 25 years, with slowly progressive pancreatic exocrine dysfunction, fatty replacement of pancreatic parenchyma (lipomatosis), and development of pancreatic cysts. Patients do not present clinical signs of chronic pancreatitis (summary by Johansson et al., 2018). For a phenotypic description and discussion of genetic heterogeneity of MODY, see 606391. [from OMIM]

Additional description

From MedlinePlus Genetics
RCAD is associated with a combination of diabetes and kidney or urinary tract abnormalities (unrelated to the elevated blood glucose), most commonly fluid-filled sacs (cysts) in the kidneys. However, the signs and symptoms are variable, even within families, and not everyone with RCAD has both features. Affected individuals may have other features unrelated to diabetes, such as abnormalities of the pancreas or liver or a form of arthritis called gout.

GCK-MODY is a very mild type of the condition. People with this type have slightly elevated blood glucose levels, particularly in the morning before eating (fasting blood glucose). However, affected individuals often have no symptoms related to the disorder, and diabetes-related complications are extremely rare.

HNF1A-MODY and HNF4A-MODY have similar signs and symptoms that develop slowly over time. Early signs and symptoms in these types are caused by high blood glucose and may include frequent urination (polyuria), excessive thirst (polydipsia), fatigue, blurred vision, weight loss, and recurrent skin infections. Over time uncontrolled high blood glucose can damage small blood vessels in the eyes and kidneys. Damage to the light-sensitive tissue at the back of the eye (the retina) causes a condition known as diabetic retinopathy that can lead to vision loss and eventual blindness. Kidney damage (diabetic nephropathy) can lead to kidney failure and end-stage renal disease (ESRD). While these two types of MODY are very similar, certain features are particular to each type. For example, babies with HNF4A-MODY tend to weigh more than average or have abnormally low blood glucose at birth, even though other signs of the condition do not occur until childhood or young adulthood. People with HNF1A-MODY have a higher-than-average risk of developing noncancerous (benign) liver tumors known as hepatocellular adenomas.

The different types of MODY are distinguished by their genetic causes. The most common types are HNF1A-MODY (also known as MODY3), accounting for 50 to 70 percent of cases, and GCK-MODY (MODY2), accounting for 30 to 50 percent of cases. Less frequent types include HNF4A-MODY (MODY1) and renal cysts and diabetes (RCAD) syndrome (also known as HNF1B-MODY or MODY5), which each account for 5 to 10 percent of cases. At least ten other types have been identified, and these are very rare.

Maturity-onset diabetes of the young (MODY) is a group of several conditions characterized by abnormally high levels of blood glucose, also called blood sugar. These forms of diabetes typically begin before age 30, although they can occur later in life. In MODY, elevated blood glucose arises from reduced production of insulin, which is a hormone produced in the pancreas that helps regulate blood glucose levels. Specifically, insulin controls how much glucose (a type of sugar) is passed from the blood into cells, where it is used as an energy source.  https://medlineplus.gov/genetics/condition/maturity-onset-diabetes-of-the-young

Clinical features

From HPO
Abdominal pain
MedGen UID:
7803
Concept ID:
C0000737
Sign or Symptom
An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen.
Exocrine pancreatic insufficiency
MedGen UID:
75647
Concept ID:
C0267963
Disease or Syndrome
Impaired function of the exocrine pancreas associated with a reduced ability to digest foods because of lack of digestive enzymes.
Elevated hemoglobin A1c
MedGen UID:
892798
Concept ID:
C4073162
Finding
An increased concentration of hemoglobin A1c (HbA1c), which is the product of nonenzymatic attachment of a hexose molecule to the N-terminal amino acid of the hemoglobin molecule. This reaction is dependent on blood glucose concentration, and therefore reflects the mean glucose concentration over the previous 8 to 12 weeks. The HbA1c level provides a better indication of long-term glycemic control than one-time blood or urinary glucose measurements.
Hyperglycemia
MedGen UID:
5689
Concept ID:
C0020456
Disease or Syndrome
An increased concentration of glucose in the blood.
Maturity onset diabetes mellitus in young
MedGen UID:
87433
Concept ID:
C0342276
Disease or Syndrome
Maturity-onset diabetes of the young is an autosomal dominant form of diabetes typically occurring before 25 years of age and caused by primary insulin secretion defects. Despite its low prevalence, MODY is not a single entity but represents genetic, metabolic, and clinical heterogeneity (Vaxillaire and Froguel, 2008). Genetic Heterogeneity of MODY MODY1 (125850) is caused by heterozygous mutation in the hepatocyte nuclear factor-4-alpha gene (HNF4A; 600281) on chromosome 20. MODY2 (125851) is caused by heterozygous mutation in the glucokinase gene (GCK; 138079) on chromosome 7. MODY3 (600496) is caused by heterozygous mutation in the hepatocyte nuclear factor-1alpha gene (HNF1A; 142410) on chromosome 12q24. MODY4 (606392) is caused by heterozygous mutation in the pancreas/duodenum homeobox protein-1 gene (PDX1; 600733) on chromosome 13q12. MODY5 (137920) is caused by heterozygous mutation in the gene encoding hepatic transcription factor-2 (TCF2; 189907) on chromosome 17q12. MODY6 (606394) is caused by heterozygous mutation in the NEUROD1 gene (601724) on chromosome 2q31. MODY7 (610508) is caused by heterozygous mutation in the KLF11 gene (603301) on chromosome 2p25. MODY8 (609812), or diabetes-pancreatic exocrine dysfunction syndrome, is caused by heterozygous mutation in the CEL gene (114840) on chromosome 9q34. MODY9 (612225) is caused by heterozygous mutation in the PAX4 gene (167413) on chromosome 7q32. MODY10 (613370) is caused by heterozygous mutation in the insulin gene (INS; 176730) on chromosome 11p15. MODY11 (613375) is caused by heterozygous mutation in the BLK gene (191305) on chromosome 8p23. MODY13 (616329) is caused by heterozygous mutation in the KCNJ11 gene (600937) on chromosome 11p15. MODY14 (616511) is caused by heterozygous mutation in the APPL1 gene (604299) on chromosome 3p14.

Professional guidelines

PubMed

Özsu E, Çetinkaya S, Bolu S, Hatipoğlu N, Savaş Erdeve Ş, Evliyaoğlu O, Baş F, Çayır A, Dündar İ, Akbaş ED, Uçaktürk SA, Berberoğlu M, Şıklar Z, Özalkak Ş, Muratoğlu Şahin N, Keskin M, Şiraz ÜG, Turan H, Öztürk AP, Mengen E, Sağsak E, Dursun F, Akyürek N, Odabaşı Güneş S, Aycan Z
J Clin Res Pediatr Endocrinol 2024 Sep 5;16(3):297-305. Epub 2024 Apr 26 doi: 10.4274/jcrpe.galenos.2024.2023-10-16. PMID: 38665000
Sanyoura M, Philipson LH, Naylor R
Curr Diab Rep 2018 Jun 22;18(8):58. doi: 10.1007/s11892-018-1024-2. PMID: 29931562Free PMC Article
Chakera AJ, Steele AM, Gloyn AL, Shepherd MH, Shields B, Ellard S, Hattersley AT
Diabetes Care 2015 Jul;38(7):1383-92. doi: 10.2337/dc14-2769. PMID: 26106223

Recent clinical studies

Etiology

Menean M, Apuzzo A, Introini U, Bandello F, Cicinelli MV
Invest Ophthalmol Vis Sci 2023 Dec 1;64(15):38. doi: 10.1167/iovs.64.15.38. PMID: 38149969Free PMC Article
Kawamoto M, Yoshida T, Tamura K, Dbouk M, Canto MI, Burkhart R, He J, Roberts NJ, Klein AP, Goggins M
Pancreatology 2022 Nov;22(7):959-964. Epub 2022 Aug 17 doi: 10.1016/j.pan.2022.08.004. PMID: 35995657Free PMC Article
Choi MH, Tjora E, Forthun RB, Engjom T, Ræder H, Hovland R, Molven A
Pancreatology 2021 Dec;21(8):1460-1465. Epub 2021 Sep 21 doi: 10.1016/j.pan.2021.09.010. PMID: 34580018

Diagnosis

Sun S, Gong S, Li M, Wang X, Wang F, Cai X, Liu W, Luo Y, Zhang S, Zhang R, Zhou L, Zhu Y, Ma Y, Ren Q, Zhang X, Chen J, Chen L, Wu J, Gao L, Zhou X, Li Y, Zhong L, Han X, Ji L
Endocrine 2024 Jan;83(1):99-109. Epub 2023 Sep 19 doi: 10.1007/s12020-023-03512-6. PMID: 37726640
Menean M, Apuzzo A, Introini U, Bandello F, Cicinelli MV
Invest Ophthalmol Vis Sci 2023 Dec 1;64(15):38. doi: 10.1167/iovs.64.15.38. PMID: 38149969Free PMC Article
El Jellas K, Dušátková P, Haldorsen IS, Molnes J, Tjora E, Johansson BB, Fjeld K, Johansson S, Průhová Š, Groop L, Löhr JM, Njølstad PR, Molven A
J Clin Endocrinol Metab 2022 Mar 24;107(4):e1455-e1466. doi: 10.1210/clinem/dgab864. PMID: 34850019Free PMC Article
Valdez-Hernández P, Pérez-Díaz I, Soriano-Rios A, Gómez-Islas V, García-Fong K, Hernández-Calleros J, Uscanga-Dominguez L, Pelaez-Luna M
Pancreas 2021 Nov-Dec 01;50(10):1376-1381. doi: 10.1097/MPA.0000000000001930. PMID: 35041336
Pellegrini S, Pipitone GB, Cospito A, Manenti F, Poggi G, Lombardo MT, Nano R, Martino G, Ferrari M, Carrera P, Sordi V, Piemonti L
J Clin Endocrinol Metab 2021 Apr 23;106(5):e2322-e2333. doi: 10.1210/clinem/dgaa986. PMID: 33417713

Prognosis

El Jellas K, Dušátková P, Haldorsen IS, Molnes J, Tjora E, Johansson BB, Fjeld K, Johansson S, Průhová Š, Groop L, Löhr JM, Njølstad PR, Molven A
J Clin Endocrinol Metab 2022 Mar 24;107(4):e1455-e1466. doi: 10.1210/clinem/dgab864. PMID: 34850019Free PMC Article

Clinical prediction guides

Menean M, Apuzzo A, Introini U, Bandello F, Cicinelli MV
Invest Ophthalmol Vis Sci 2023 Dec 1;64(15):38. doi: 10.1167/iovs.64.15.38. PMID: 38149969Free PMC Article
El Jellas K, Dušátková P, Haldorsen IS, Molnes J, Tjora E, Johansson BB, Fjeld K, Johansson S, Průhová Š, Groop L, Löhr JM, Njølstad PR, Molven A
J Clin Endocrinol Metab 2022 Mar 24;107(4):e1455-e1466. doi: 10.1210/clinem/dgab864. PMID: 34850019Free PMC Article
Gravdal A, Xiao X, Cnop M, El Jellas K, Johansson S, Njølstad PR, Lowe ME, Johansson BB, Molven A, Fjeld K
J Biol Chem 2021 Jan-Jun;296:100661. Epub 2021 Apr 14 doi: 10.1016/j.jbc.2021.100661. PMID: 33862081Free PMC Article
Dalva M, Lavik IK, El Jellas K, Gravdal A, Lugea A, Pandol SJ, Njølstad PR, Waldron RT, Fjeld K, Johansson BB, Molven A
Cells 2020 Jan 18;9(1) doi: 10.3390/cells9010244. PMID: 31963687Free PMC Article
Torsvik J, Johansson BB, Dalva M, Marie M, Fjeld K, Johansson S, Bjørkøy G, Saraste J, Njølstad PR, Molven A
J Biol Chem 2014 Oct 17;289(42):29097-111. Epub 2014 Aug 25 doi: 10.1074/jbc.M114.574244. PMID: 25160620Free PMC Article

Recent systematic reviews

Sun S, Gong S, Li M, Wang X, Wang F, Cai X, Liu W, Luo Y, Zhang S, Zhang R, Zhou L, Zhu Y, Ma Y, Ren Q, Zhang X, Chen J, Chen L, Wu J, Gao L, Zhou X, Li Y, Zhong L, Han X, Ji L
Endocrine 2024 Jan;83(1):99-109. Epub 2023 Sep 19 doi: 10.1007/s12020-023-03512-6. PMID: 37726640

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...